scPharmaceuticals, Inc. (SCPH): Price-to-Revenue Coefficient

Symbol and logo of brand scPharma (SCPH)

scPharmaceuticals Inc. (SCPH) cash flows are protected by patents for furosemide delivery systems and stringent FDA controls. The company's price-to-sales ratio clearly confirms this trend, where the value 6.00 represents the current metric. While high global growth potential is based on intellectual property, financial stability currently relies solely on the success of a single flagship product.

SCPH scpharmaceuticals.com: Price-to-Revenue Ratio in the range 05/21/2023 - 10/18/2025

Analytical breakdowns for scPharmaceuticals Inc. (SCPH)

- share price and consensus valuation forecast:
Price Performance Chart scpharmaceuticals.com|SCPH - Price Target Chart
- stock exchange capitalization data:
Market Capitalization scPharma|SCPH - Enterprise Value
- company book value details:
Accounting Value per Share scPharmaceuticals|SCPH - Company Book Value|Market Capitalization to Net Assets scpharmaceuticals.com|SCPH - Company Total Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio scPharmaceuticals Inc.|SCPH - Long-Term Debt to Capital|Short-Term Debt to Capital scpharmaceuticals.com|SCPH - Company Debts|Debt to Net Assets Ratio scPharma|SCPH - Company Long-Term Debt|Company Current Liabilities scPharmaceuticals|Quick Ratio scpharmaceuticals.com
- business earnings and investment ratios data:
SCPH - Net Profit|Future Profit scPharmaceuticals Inc.|SCPH - P/E Multiple|Projected Price to Earnings Ratio scpharmaceuticals.com|SCPH - Price/Earnings to Growth Multiple|EV/EBITDA Multiple scPharma|SCPH - Operating profit before deduction of amortization|Earnings per share for the last four quarters scPharmaceuticals|SCPH - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months scpharmaceuticals.com|SCPH - Earnings growth in current year|Expected earnings per share growth for next year scPharmaceuticals Inc.
- total revenue and sales volume data:
SCPH - Revenue and Sales Volume|Projected Sales Volume scpharmaceuticals.com|SCPH - Price-to-Revenue Ratio|Price-to-Projected Revenue Ratio scPharma
Fundamental company analysis:scPharmaceuticals, Inc., SCPH
Finished products of scPharmaceuticals Inc.

For scPharmaceuticals Inc. (SCPH), which monetizes home treatment for heart failure via the Furoscix system, this indicator determines the market value of each unit of generated revenue. By analyzing the P/S multiple, an investor compares market capitalization with revenue from insurance reimbursements, allowing for an assessment of the premium paid for business scaling potential and the sustainability of the valuation amid the transition of patients from inpatient to home care.

Competitors of scPharmaceuticals Inc.

HLN (haleon.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kenvue KVUE|Price-to-Revenue Coefficient Verona Pharma PLC (VRNA)|Jyong Biotech Corp - P/S Multiple|Ligand Corp (LGND) - Market Cap to Revenue|Amneal Pharmaceuticals (AMRX) - Price-to-Revenue Ratio|Price-to-Sales Ratio PRGO (perrigo.com)|ALVO (Alvotech SA) - P/S Multiple|LQDA: Market Capitalization-to-Revenue Ratio|P/S Multiple GLPG|P/S Multiple ANI Pharmaceuticals Corp (ANIP)|Price-to-Revenue Ratio MannKind Corporation MNKD|Market Capitalization-to-Revenue Ratio AMPH|PCRX - Price-to-Revenue Ratio|ARS Pharmaceuticals Inc (SPRY) - Market Cap to Revenue|TBPH: P/S Multiple|Aquestive Corp (AQST) - P/S Multiple|TECX (Tectonic Therapeutic Inc.) - P/S Multiple|Market Cap to Revenue tonixpharma.com (TNXP)|P/S Multiple SXTC|EPRX - Price to Sales|BioHarvest - Market Cap to Revenue|P/S Multiple Invizyne EXOZ|ORMP: Market Cap to Revenue|Entera Bio Ltd. - Market Cap to Sales Volume|HYFT: P/S Multiple|ABVC - Price-to-Revenue Coefficient|CPIX (Cumberland Pharma) - P/S Multiple|Market Cap to Revenue Quantum BioPharma Corp (QNTM)|P/S Multiple FGEN|P/S Multiple telomirpharma.com (TELO)|Price-to-Revenue Ratio Rani Therapeutics Holdings, Inc. RANI|Synergy CHC Corp. - Price-to-Revenue Ratio|RLYB - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Lexaria Bioscience LEXX|PULM (Pulmatrix, Inc.) - Market Cap to Revenue|Pheton Holdings - Market Capitalization-to-Revenue Ratio|APM (Aptorum Group Ltd) - P/S Multiple|Lyra Therapeutics Inc. (LYRA) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Impact BioMedical (IBO)|tnfpharma.com - Market Cap to Revenue Ratio|P/S Multiple YCBD (cbdMD)|PRFX - Market Cap to Revenue|CYTO: Market Cap to Revenue|Price-to-Revenue Coefficient Lipella Pharmaceuticals Inc LIPO|Optinose (OPTN) - Price-to-Revenue Ratio|PIRS - Price-to-Revenue Coefficient|PROC (Procaps Group S.A.) - P/S Multiple|Market Cap to Revenue petrospharma.com (PTPI)|Price-to-Revenue Ratio Qilian International Holding (QLI)|SLRN: Price-to-Sales Ratio|P/S Multiple TFFP (TFF Pharma)